Lupin Expects Respiratory Ramp Up From Fiscal '22
Generics To Benefit From US Election Outcome
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
You may also be interested in...
Lupin delivered a shaky Q3 as profit margins fell following complications with metformin and oseltamivir, but the firm appears confident that several impending high-value launches will set it back on the right track.
Following Lupin’s launch of the first UK generic version of Fostair in August, Lupin UK general manager Ben Ellis tells Generics Bulletin how the company is taking full advantage of the opportunity and laying the groundwork for future activities in the respiratory arena.
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.